Trial Profile
A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2021
Price :
$35
*
At a glance
- Drugs ST 266 (Primary)
- Indications Corneal disorders
- Focus Therapeutic Use
- Sponsors Noveome
- 18 Sep 2020 Status changed from active, no longer recruiting to completed.
- 22 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2020 According to a Noveome media release, data (as of data cutoff date, n=11) from this study was published today as an online presentation for the Association for Research in Vision and Ophthalmology (ARVO) 2020 Online Presentations and its associated platform, ARVOLearn.